Volume 150, Issue 2, Pages 299-306 (August 2016) High Level of Chemokine CCL18 Is Associated With Pulmonary Function Deterioration, Lung Fibrosis Progression, and Reduced Survival in Systemic Sclerosis Anna-Maria Hoffmann-Vold, MD, PhD, Anders Heiervang Tennøe, MD, Torhild Garen, Øyvind Midtvedt, MD, Aurelija Abraityte, Trond Mogens Aaløkken, MD, PhD, May Britt Lund, MD, PhD, Cathrine Brunborg, Pål Aukrust, MD, Prof, Thor Ueland, MD, Prof, Øyvind Molberg, MD, Prof CHEST Volume 150, Issue 2, Pages 299-306 (August 2016) DOI: 10.1016/j.chest.2016.03.004 Copyright © 2016 American College of Chest Physicians Terms and Conditions
Figure 1 Boxplot showing serum levels of CCL18 in patients with SSc and healthy control subjects. Broken line indicates the cutoff of 53 ng/mL. SSc = systemic sclerosis. CHEST 2016 150, 299-306DOI: (10.1016/j.chest.2016.03.004) Copyright © 2016 American College of Chest Physicians Terms and Conditions
Figure 2 FVC > 10% decline, FVC < 70% at follow-up, and survival in patients with SSc with short disease duration stratified by high (Red bars) and low (Blue bars) CCL18 serum levels. See Figure 1 legend for expansion of abbreviation. CHEST 2016 150, 299-306DOI: (10.1016/j.chest.2016.03.004) Copyright © 2016 American College of Chest Physicians Terms and Conditions
Figure 3 A, Cumulative survival of patients with systemic sclerosis stratified by CCL18 level. B, Cumulative survival of patients with systemic sclerosis with short disease duration stratified by CCL18 level. High (Blue lines) and low (Red lines) CCL18 levels are reported below the figure in ng/mL. CHEST 2016 150, 299-306DOI: (10.1016/j.chest.2016.03.004) Copyright © 2016 American College of Chest Physicians Terms and Conditions